A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

This study is currently recruiting participants.
Verified March 2013 by Boryung Pharmaceutical Co., Ltd
Sponsor:
Collaborators:
Gachon University Gil Medical Center
The Catholic University of Korea
Gyungbook national university hospital
Daegu Catholic University Medical Center
Wonkwang university Hospital
Wonju Severance Christian Hospital
Korea University Guro Hospital
DongGuk University
Yeungnam University
Chonnam National University Hospital
Cheil General Hospital and Women’s Healthcare Center
Chungnam National University
Asan Medical Center
Seoul National University Bundang Hospital
Inha University Hospital
Seoul National University Hospital
Inje University
Samsung Medical Center
Busan university Yangsan Hospital
soon chun hyang University Hospital Seoul
Catholic University of Korea St. Paul's Hospital
Hallym University Medical Center Kang-Dong
Jeju National University Hospital
Hanyang University Seoul Hoapital
Kangbuk Samsung Medical center
Information provided by (Responsible Party):
Boryung Pharmaceutical Co., Ltd
ClinicalTrials.gov Identifier:
NCT01518998
First received: January 24, 2012
Last updated: March 26, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)